Financing ·
Vivos Inc. raises $1M via Reg A+ equity offering and issues warrants
RDGLVivos Inc
On October 30, 2026, Vivos Inc. completed the sale of 12,500,000 shares of common stock in a Regulation A+ best-efforts offering, generating gross proceeds of $1,000,000 for general working capital. The company also issued warrants to purchase 25,000,000 additional shares to accredited investors for $25,000, exercisable at $0.075 per share and expiring December 31, 2030. Additionally, Vivos exchanged 8,000,000 warrants for 8,000,000 shares of common stock. The company will hold its annual meeting on December 9, 2026. Vivos Inc. operates in the medical device industry, focusing on minimally invasive treatments for sleep apnea and bruxism.